Sign in
TerminatedPhase 2

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
1 person enrolled
Started
8 May 2023
Ended
25 Dec 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Pioglitazone 15mg
Record updated
28 April 2026
Why it stopped
Loss of Financial Sponsor

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Age 18-80 years
  • CT scan demonstrating an acute, spontaneous, primary basal ganglia ICH
  • ICH volume between 30 - 80 mL as calculated by the ABC/2 method
  • Study intervention can reasonably be initiated within 24 hours after the onset of stroke symptoms. In situations with unclear time of onset, then the onset will be considered the time that the subject was last known to be well
  • Glasgow Coma Score (GCS) 5 - 14
  • Historical Modified Rankin Score 0 or 1
  • Consent by patient or LAR to MIS evacuation of the ICH based on best medical practice1
  • Time to pioglitazone treatment ≤ 24 hours from symptom onset or TLKN1

Who cannot take part

  • Participation in a concurrent interventional medical investigation or clinical trial
  • Known life-expectancy of less than 6 months, no reasonable expectation of recovery, Do-Not-Resuscitate (DNR), or comfort measures only prior to randomization
  • T2DM treated with insulin or an oral medication including Glyburide, unless the NICU physician deems it safe to replace the T2DM medication with pioglitazone1
  • Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, moyamoya disease, hemorrhagic conversion of an ischemic infarct, or bleeding into a known neoplastic lesion
  • NIHSS< 5, bilateral fixed dilated pupils, extensor motor posturing, unstable mass or evolving intracranial compartment syndrome
  • Intraventricular extension of the hemorrhage estimated to involve >50% of either of the lateral ventricles (External ventricular drain (EVD) to treat intracranial pressure (ICP) or hydrocephalus is allowed)
  • Primary thalamic ICH or infratentorial intraparenchymal hemorrhage including midbrain, pons or cerebellum
  • Evidence of active bleeding involving a retroperitoneal, gastrointestinal, genitourinary, or respiratory tract site
  • Use of anticoagulants that cannot be rapidly reversed, uncorrected coagulopathy or known clotting disorder
  • Patients with a mechanical heart valve (presence of bioprosthetic valve(s) is permitted)
  • Homelessness or history of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • intolerance or allergy to any TZD1
  • heart failure (symptomatic or NYHA Class I-IV or newly diagnosed on admission TTE screening)
  • Severe kidney or liver disease (serum ALT > 2.5 x ULN) with active coagulopathy
  • Platelet count < 75,000
  • International Normalized Ratio (INR) > 1.4 after correction or inability to sustain INR ≤ 1.4 using short- and long-active procoagulants (such as, but not limited to, NovoSeven, fresh frozen plasma, vitamin K, Kcentra or Feiba)
  • Untreatable elevated activated partial thromboplastin time (aPTT)
  • Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or is post-menopausal
  • patients with abnormal (>1x upper limit of normal) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin
  • Patients requiring long-term anticoagulation that needs to be initiated < 5 days from index ICH; patient must not require Coumadin (anticoagulation) during the first 30 days (reversal of anticoagulation is permitted for medically stable patients who can safely tolerate the short-term risk of reversal)
  • Inability or unwillingness of subject or legal guardian/representative to give written informed consent

Where in United States

  • University of Maryland, BaltimoreBaltimore, United States

About the trial

What the trial wants to find out

This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.

The 2 groups in the trial

  • MIPS + PioglitazoneTreatment being tested

    20 Subjects will undergo MIPS for evacuation of ICH using the BrainPath access device plus perioperative pioglitazone for 3 weeks

    Treatment: Pioglitazone 15mg

  • MIPS AloneNo study treatment, for comparison

    This trial will compare it's subjects to subjects who have previously undergone MIPS for evacuation of ICH using the BrainPath access device as part of the ENRICH trial (NCT02880878). These subjects will be enrolled at an ENRICH trial site independent of our Institution. Deidentified patient information from 20 subjects in this group, who will be matched to those in the ENRICH-PLUS group, will be provided to the principal investigator for comparison of outcomes.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Non-Randomized Controlled Trial to Examine the Safety and Suitability of Supplementing Early Minimally Invasive Parafascicular Surgery (MIPS) for Clot Evacuation of Basal Ganglia Intracerebral Hemorrhage (ICH) With Pioglitazone
Record updated
28 April 2026